Mechanisms of antimicrobial resistance in Gram-negative bacilli

Abstract

The burden of multidrug resistance in Gram-negative bacilli (GNB) now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients. In Enterobacteriaceae, the dramatic increase in the rates of resistance to third-generation cephalosporins mainly results from the spread of plasmid-borne extended-spectrum beta-lactamase (ESBL), especially those belonging to the CTX-M family. The efficacy of beta-lactam/beta-lactamase inhibitor associations for severe infections due to ESBL-producing Enterobacteriaceae has not been adequately evaluated in critically ill patients, and carbapenems still stands as the first-line choice in this situation. However, carbapenemase-producing strains have emerged worldwide over the past decade. VIM- and NDM-type metallo-beta-lactamases, OXA-48 and KPC appear as the most successful enzymes and may threaten the efficacy of carbapenems in the near future. ESBL- and carbapenemase-encoding plasmids frequently bear resistance determinants for other antimicrobial classes, including aminoglycosides (aminoglycoside-modifying enzymes or 16S rRNA methylases) and fluoroquinolones (Qnr, AAC(6')-Ib-cr or efflux pumps), a key feature that fosters the spread of multidrug resistance in Enterobacteriaceae. In non-fermenting GNB such as Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia, multidrug resistance may emerge following the sole occurrence of sequential chromosomal mutations, which may lead to the overproduction of intrinsic beta-lactamases, hyper-expression of efflux pumps, target modifications and permeability alterations. P. aeruginosa and A. baumannii also have the ability to acquire mobile genetic elements encoding resistance determinants, including carbapenemases. Available options for the treatment of ICU-acquired infections due to carbapenem-resistant GNB are currently scarce, and recent reports emphasizing the spread of colistin resistance in environments with high volume of polymyxins use elicit major concern.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 172

1. 1.

   Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and managment. Curr Opin Pulm Med. 2013;19(3):216-228.

   Not in our library10.1097/mcp.0b013e32835f27be

2. 2.

   REA-Raisin Network (2012) Surveillance of nosocomial infections in critically ill adult patients, France, 2012. http://www.cclinparisnord.org. Accessed 26 Dec 2014

   Not in our library

3. 3.

   Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009. Am J Infect Control. 2012;40(5):396-407.

   Not in our library10.1016/j.ajic.2011.05.020

4. 4.

   Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

   Not in our library10.1007/s00134-012-2769-8

5. 5.

   European Center for Disease Control and Prevention (2013) European Antimicrobial Resistance Surveillance (EARS-Net) 2013. http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance. Accessed 29 Dec 2014

   Not in our library

6. 6.

   Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81-S87.

   Not in our library10.1086/653053

7. 7.

   Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents. 2014;43(4):328-334.

   Not in our library10.1016/j.ijantimicag.2014.01.007

8. 8.

   Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409-1417.

   Not in our library10.1164/rccm.201102-0349oc

9. 9.

   Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis. 2014;78(4):443-448.

   Not in our library10.1016/j.diagmicrobio.2013.11.025

10. 10.

    Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985-995.

    Not in our library10.1164/rccm.201301-0079oc

11. 11.

    Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: an European perspective. Thorax. 2013;68:997-999.

    Not in our library10.1136/thoraxjnl-2013-203384

12. 12.

    Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med. 2012;38(11):1769-1778.

    Not in our library10.1007/s00134-012-2675-0

13. 13.

    Hsueh P-R, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents. 2010;36:408-414.

    Not in our library10.1016/j.ijantimicag.2010.07.002

14. 14.

    Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas S, et al. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J. 2015;45(5):1353-1363.

    Not in our library10.1183/09031936.00152514

15. 15.

    Center for Diseases Control and Prevention (2013) Threat report 2013. http://www.cdc.gov. Accessed 13 Mar 2015

    Not in our library

16. 16.

    Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128(6):1037-1050.

    Not in our library10.1016/j.cell.2007.03.004

17. 17.
    Antibiotic stewardship in the intensive care unit · 2014

    No notice
18. 18.

    Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41(5):776-795.

    Not in our library10.1007/s00134-015-3719-z

19. 19.
    Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008 · 2010

    No notice
20. 20.

    Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321-331.

    Not in our library10.1098/rstb.1980.0049

21. 21.

    Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-182.

    Not in our library10.1128/cmr.00036-08

22. 22.

    Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19(2):141-160.

    Not in our library10.1111/j.1469-0691.2011.03703.x

23. 23.

    Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect. 2004;10(1):84-85.

    Not in our library10.1111/j.1469-0691.2004.00831.x

24. 24.

    Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012;40(4):297-305.

    Not in our library10.1016/j.ijantimicag.2012.06.004

25. 25.

    Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect. 2002;8(12):823-825.

    Not in our library10.1046/j.1469-0691.2002.00492.x

26. 26.

    Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57(3):1488-1495.

    Not in our library10.1128/aac.01823-12

27. 27.

    Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781-788.

    Not in our library10.1093/cid/cit395

28. 28.

    Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents. 2013;41(3):236-249.

    Not in our library10.1016/j.ijantimicag.2012.10.022

29. 29.

    American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.

    Not in our library10.1164/rccm.200405-644st

30. 30.

    Thiebaut AC, Arlet G, Andremont A, Papy E, Sollet JP, Bernede-Bauduin C, et al. Variability of intestinal colonization with third-generation cephalosporin-resistant Enterobacteriaceae and antibiotic use in intensive care units. J Antimicrob Chemother. 2012;67(6):1525-1536.

    Not in our library10.1093/jac/dks072

31. 31.

    Grohs P, Podglajen I, Guerot E, Bellenfant F, Caumont-Prim A, Kac G, et al. Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling. Clin Microbiol Infect. 2014;20(11):O879-O886.

    Not in our library10.1111/1469-0691.12663

32. 32.

    Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother. 2013;68(11):2667-2674.

    Not in our library10.1093/jac/dkt212

33. 33.

    Beta-lactamase classification and amino-acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor-resistant enzymes. http://www.lahey.org/studies. Accessed 23 Mar 2015

    Not in our library

34. 34.

    Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis. 1988;10(4):850-859.

    Not in our library10.1093/clinids/10.4.850

35. 35.

    Quale JM, Landman D, Bradford PA, Visalli M, Ravishankar J, Flores C, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis. 2002;35(7):834-841.

    Not in our library10.1086/342577

36. 36.

    Mammeri H, Laurans G, Eveillard M, Castelain S, Eb F. Coexistence of SHV-4- and TEM-24-producing Enterobacter aerogenes strains before a large outbreak of TEM-24-producing strains in a French hospital. J Clin Microbiol. 2001;39(6):2184-2190.

    Not in our library10.1128/jcm.39.6.2184-2190.2001

37. 37.

    Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant Klebsiellapneumoniae and Escherichia coli in nursing homes. JAMA. 1999;281(6):517-523.

    Not in our library10.1001/jama.281.6.517

38. 38.

    Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob Agents Chemother. 1996;40(2):509-513.

    Not in our library10.1128/aac.40.2.509

39. 39.

    Matsumoto Y, Ikeda F, Kamimura T, Yokota Y, Mine Y. Novel plasmid-mediated beta-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother. 1998;32:1243-1246.

    Not in our library10.1128/aac.32.8.1243

40. 40.

    Barthelemy M, Peduzzi J, Bernard H, Tancrède C, Labia R. Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum beta-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca. Biochim Biophys Acta. 1992;1122(1):15-22.

    Not in our library10.1016/0167-4838(92)90121-s

Cited by papers we hold 9

• High prevalence of bla CTX-M and bla SHV among ESBL producing E. coli isolates from beef cattle in China’s Sichuan-Chongqing Circle · 2021
  Not checked
• Acinetobacter baumannii Infections in Times of COVID-19 Pandemic · 2021
  No notice
• Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It · 2020
  No notice
• Streamlined Genetic Manipulation of Diverse Bacteroides and Parabacteroides Isolates from the Human Gut Microbiota · 2019
  No notice
• The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How · 2019
  No notice
• The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections · 2017
  Corrected
• Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria? · 2017
  No notice
• Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health · 2017
  No notice
• Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) · 2016
  Corrected

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.